Navigation Links
Hallucinogen appears safe, may improve mood among patients with advanced-stage cancer and anxiety
Date:9/6/2010

A pilot study suggests the hallucinogen psilocybin may be feasible and safe to administer to patients with advanced-stage cancer and anxiety, with promising effects on mood, according to a report published online today that will appear in the January 2011 print issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

"In recent years, there has been a growing awareness that the psychological, spiritual and existential crises often encountered by patients with cancer and their families need to be addressed more vigorously," the authors write as background information in the article. "From the late 1950s to the early 1970s, research was carried out exploring the use of hallucinogens to treat the existential anxiety, despair and isolation often associated with advanced-stage cancer. Those studies described critically ill individuals undergoing psychospiritual epiphanies, often with powerful and sustained improvement in mood and anxiety as well as diminished need for narcotic pain medication."

Despite initial promising results, no follow-up research had been conducted; however, the medical value of hallucinogens is now being re-examined in psychiatric settings, the authors note. Charles S. Grob, M.D., of Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, Torrance, explored the safety and efficacy of psilocybina hallucinogen with some psychological effects similar to lysergic acid diethylamide (LSD)among 12 adults with advanced-stage cancer and anxiety.

Participants served as their own controls; in two six-hour treatment sessions several weeks apart, they were given clear capsules either of active psilocybin (in a dose of 0.2 milligrams per kilogram) or a placebo (niacin, 250 milligrams) in random order. Physiological responses such as blood pressure, heart rate and temperature were measured before and after, and psychological measures including assessments of depression, mood and anxiety were administered before and at the end of the session, one day and two weeks after the session and at monthly intervals for the following six months.

"Safe physiological and psychological responses were documented during treatment sessions," the authors write. "We also observed no adverse psychological effects from the treatment. All subjects tolerated the treatment sessions well, with no indication of severe anxiety or a 'bad trip.'" In addition, anxiety scores improved at one and three months after treatment and a depression inventory revealed an improvement of mood that began two weeks after treatment and reached significance at six months.

"This study established the feasibility and safety of administering moderate doses of psilocybin to patients with advanced-stage cancer and anxiety," the authors conclude. "Some of the data revealed a positive trend toward improved mood and anxiety. These results support the need for more research in this long-neglected field."


'/>"/>

Contact: Laura Mecoy
Lmecoy@issuesmanagement.com
310-546-5860
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. FDA Panel Appears Skeptical Over Key Avandia Data
2. Plasma protein appears to be associated with development and severity of Alzheimers disease
3. Celebrex Appears Easier on Stomach for Arthritis Patients
4. NAMI Medical Director Honored with APA Patient Advocacy Award; Appears in CNN Health and Huffington Post Columns
5. Taking Flu Drugs While Pregnant Appears to Be Safe: Study
6. Hospitalization Appears to Help Personality Disorder Patients
7. How health care is paid for appears to impact outcome
8. Protein Appears Key to Intestinal Balance
9. Eggs Being Produced by Recall Farms Safe, if Pasteurized, Experts Say
10. Drug-eluting stents confirmed safe, effective for long-term use
11. Declare Your Skin-dependence this Holiday with Patriotic, Playful Products from TruKid, the Award-Winning Line of Safe, Natural Products for Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... August 17, 2017 , ... ... Wednesday, August 16, to community partners. The newly renovated ER was designed with ... for minor emergencies, eight semi-private rooms to deliver patient results, improve efficiencies and ...
(Date:8/17/2017)... ... August 17, 2017 , ... ... to Healing Through Forgiveness ($15.99, paperback, 9781498497626; $7.99, eBook, 9781498497633) focuses on ... inner healing of memories and achieve forgiveness, through a progressive journey toward healing. ...
(Date:8/17/2017)... ... , ... Advice Media, the industry leader in digital marketing for medical practices, has been recognized ... included in the Inc. 5000 for the second time in two years. Shawn Miele, Chief ... 5000 rankings for the second year in a row. It’s extremely difficult to make this ...
(Date:8/16/2017)... ... ... Summer days spent with family are priceless. Since August is Family Fun Month, ... season of sunshine. Add trying something new to this summer’s bucket list. Whether it’s ... fun. , Try Something New , Choose an activity the whole ...
(Date:8/16/2017)... ... ... Ten outstanding teachers in the Greater Houston area will be named one ... by a Houston Texans player, two tickets to a Texans game, and other prizes. ... texanschecking.com/stars to nominate their favorite teacher with an essay of no more than 500 ...
Breaking Medicine News(10 mins):
(Date:7/26/2017)... LOVELAND, Colo. , July 26, 2017 ... Tristan Guttridge and the Bimini SharkLab to custom design the ... diagnostic images of sharks in their native habitat. In ... for Discovery Channel,s Shark Week, Dr. Guttridge approached ... to take pregnancy diagnosis directly to hammerhead sharks underwater. ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals ... of our clinical trial evaluating Altemia TM , an ... (SCA) and Sickle Cell Disease (SCD). The SCOT Trial, ... the efficacy and safety of Altemia TM in ... conducted under US IND 125274. ...
(Date:7/25/2017)... CAMBRIDGE, Massachusetts , July 25, 2017 /PRNewswire/ ... drugs to treat rare nervous system diseases, has concluded a ... and market the drug SOM0226 against transthyretin amyloidosis (ATTR). Before ... promising results in a Phase 2 study conducted in ... in the United States ...
Breaking Medicine Technology: